Marker Therapeutics (NASDAQ:MRKR) Announces Earnings Results

Marker Therapeutics (NASDAQ:MRKR) announced its quarterly earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.17, FiscalAI reports. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. The business had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $0.68 million.

Marker Therapeutics Stock Performance

MRKR stock traded down $0.02 during midday trading on Wednesday, reaching $1.34. 73,038 shares of the company traded hands, compared to its average volume of 328,445. The firm has a market capitalization of $22.34 million, a price-to-earnings ratio of -1.09 and a beta of 1.42. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $4.07. The business has a 50 day moving average of $1.63 and a 200-day moving average of $1.29.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on MRKR. UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Marker Therapeutics in a report on Monday, December 22nd. Wall Street Zen raised Marker Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. HC Wainwright began coverage on shares of Marker Therapeutics in a report on Monday, December 8th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Zacks Research cut shares of Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Marker Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $11.25.

Hedge Funds Weigh In On Marker Therapeutics

Several hedge funds have recently added to or reduced their stakes in MRKR. Virtu Financial LLC acquired a new stake in Marker Therapeutics in the third quarter valued at approximately $25,000. Two Sigma Investments LP purchased a new stake in shares of Marker Therapeutics during the 3rd quarter valued at $33,000. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics in the 2nd quarter worth $33,000. XTX Topco Ltd grew its stake in Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after buying an additional 36,269 shares during the last quarter. Finally, LPL Financial LLC grew its stake in Marker Therapeutics by 41.7% during the 4th quarter. LPL Financial LLC now owns 83,247 shares of the company’s stock worth $124,000 after buying an additional 24,500 shares during the last quarter. 22.39% of the stock is currently owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.